No Data
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
Piper Sandler Remains a Buy on BridgeBio Pharma (BBIO)
Optimistic Buy Rating for BridgeBio Pharma Due to Strong Launch and Strategic Initiatives
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $49
Express News | HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $49 Price Target
BridgeBio Pharma Analyst Ratings